Quarterly report pursuant to Section 13 or 15(d)

Development Awards and Deferred Revenue (Details Narrative)

v3.10.0.1
Development Awards and Deferred Revenue (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 26, 2018
Apr. 20, 2015
Apr. 20, 2015
Nov. 30, 2017
Jan. 31, 2017
Aug. 31, 2016
Nov. 30, 2015
May 31, 2015
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Development Award [Line Items]                          
Amount received upon achievement                       $ 12,500,000  
Revenue                 $ 853,646   $ 350,186 $ 1,804,088 $ 1,643,883
Warrant to purchase of common stock                 2,288,500     2,288,500  
Warrant exercisable price per share                 $ 6.33     $ 6.33  
Additional paid in capital, fair value of warrant issued                       $ 6,215,225  
Cystic Fibrosis Foundation Warrants [Member]                          
Development Award [Line Items]                          
Revenue                       $ 18,784,775  
Warrant to purchase of common stock 1,000,000               1,000,000     1,000,000  
Warrant exercisable price per share $ 13.20               $ 13.20     $ 13.20  
Warrant exercisable shares of common stock 500,000               500,000     500,000  
Warrant expires date Jan. 26, 2025                        
Additional paid in capital, fair value of warrant issued                       $ 6,215,225  
2015 CFFT Award Agreement [Member]                          
Development Award [Line Items]                          
Amount received upon achievement       $ 500,000 $ 1,000,000 $ 1,000,000 $ 1,250,000 $ 1,250,000          
Revenue                   $ 350,816 $ 1,643,883
2015 CFFT Award Agreement [Member] | Oral Anti-inflammatory Drug [Member]                          
Development Award [Line Items]                          
Amount received upon achievement     $ 5,000,000                    
2015 CFFT Award Agreement [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]                          
Development Award [Line Items]                          
Payment due period after the first commercial sale   90 days                      
Royalty payment, sales target   $ 500,000,000 500,000,000                    
2015 CFFT Award Agreement [Member] | Maximum [Member]                          
Development Award [Line Items]                          
Development award received   5,000,000 $ 5,000,000                    
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Commercialization of the Product [Member]                          
Development Award [Line Items]                          
Royalty payable   25,000,000                      
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]                          
Development Award [Line Items]                          
Royalty payable   5,000,000                      
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Transfer Sale or Licensing [Member]                          
Development Award [Line Items]                          
Royalty payable   $ 15,000,000                      
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                          
Development Award [Line Items]                          
Development award received $ 25,000,000                        
Investment Agreement [Member]                          
Development Award [Line Items]                          
Revenue                 853,646     1,804,088  
Reclassified to contract asset and classified in prepaid expenses                       25,000,000  
Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                          
Development Award [Line Items]                          
Amount received upon achievement                 $ 6,250,000 $ 6,250,000   $ 12,500,000  
Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member]                          
Development Award [Line Items]                          
Warrant exercisable shares of common stock 500,000               500,000     500,000  
Warrant expires date                       Jan. 26, 2025  
Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                          
Development Award [Line Items]                          
Amount received upon achievement                       $ 6,250,000